Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early , the company’s cancer has. Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to. Abgenix, Inc. will become the sole owner of the XenoMouseâ„¢, a leading technology for generating fully human antibody drugs useful in.

Author: Yodal Tokinos
Country: Cambodia
Language: English (Spanish)
Genre: Marketing
Published (Last): 7 October 2011
Pages: 413
PDF File Size: 20.17 Mb
ePub File Size: 16.5 Mb
ISBN: 373-6-81895-889-3
Downloads: 54697
Price: Free* [*Free Regsitration Required]
Uploader: Nagor

Also, it can be determined whether there are any strategic learning opportunities associated with each of the options. Hybridoma lymph nodes murine Abgenix Xenomouse 6. This would entitle the company with a much higher bargaining power when entering the negotiations to choose a partner.

Get the latest articles from Bioprocess Online delivered to your inbox. In return, Abgenix will receive a technology access payment and could receive additional fees and milestone payments plus royalties on future product sales by Chiron.

Glick Porter Novelli Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy.

Abgenix and the XenoMouse

Thus, having Xenomoouse as a resource renders possible a vast array of antibody therapies, the development of which can either be undertaken in-house or licensed to a corporate collaborator for payment of, typically, an upfront fee, early development fees as well as royalties following market launch of a given treatment.

Scott Greer, president and chief executive officer of Abgenix.

These permits may be required for shipping this product: Statements made in this press release about Abgeniix XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix’s patent portfolio.


For more information on Abgenix, visit the company’s Web site at www. Once antibodies for a specific target have been developed, Abgenix has in-house abgenid capabilities xenokouse carry the therapy based hereupon through preclinical trials and until phase II clinical trials. In Aprilthe biopharmaceutical company Abgenix faced the important strategic decision of how to most profitably commercialize its XenoMouse based high potential cancer product ABX-EGF, which had reached phase I clinical trials after having successfully passed preclinicals.

Xenomouse Case Study Analysis

Thus, Abgenix capabilities do not reach beyond phase II clinical trials, for which reason the company does not have a resource base capable of commercializing an antibody drug, e. However, the company did have the in-house capabilities of taking the drug through the second phase of clinical testing.

Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, and cancer.

In order to arrive at conclusions as to which alternative Abgenix should opt for, the three alternatives are analyzed in the following pages based on a financial assessment in the form of strategic abggenix as well as an NPV analysis. The joint venture entails co-development work in phase II, whereas Biopart will take the lead in subsequent phases exnomouse in what concerns commercialization activities.

Abgenix also will provide JT with licenses to related technology.

Please see Abgenix’s public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix. Skip to main content Contact: Permits Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required.

This deal also represents the eighth new potential product candidate being pursued by one of our XenoMouse collaborators this year. The patent issued as U. Glick Porter Novelli Disclaimer: The marketing and sales barriers to entry not being scalable, Abgenix would be forced, at one point or another, to either partner or sell its rights on ABX-EGF.


Xenomouse Case Study Analysis – Doing What Matters

XenoMouse technology offers the following advantages: JT to relinquish certain option and license rights it is currently entitled to. Abgenix has collaborative arrangements with a number of pharmaceutical and biotechnology companies involving its XenoMouse technology.

Abgenix has collaborative arrangements with multiple pharmaceutical and biotechnology companies involving its XenoMouse technology.

A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment. Given that the company has very good expectations for ABX-EGF making it to that stage, a then increased value could allow them to renegotiate the partnership with Biopart in terms of percentage of xenomoueewhich would translate into a more dense stream of revenues.

Transgenic Mice That Produce Fully Humanized Antibodies — Abgenix Granted Patent

Accordingly, specialized complementary assets are definitely required for Abgenix in order to bring ABX-EGF to market as their current resources are limited to taking a product to the end abegnix phase II and no current sales organization exists. Company Profile Email Us. Furthermore they miss an opportunity to have some profit with this product. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished.

For all antibody products generated using XenoMouse technology and developed by JT, JT will make license fee payments to Abgenix as well as royalty payments on any product sales.

Utilizing XenoMouse, Abgenix has a competitive advantage in antibody development to specific disease targets, which normally are discovered and validated by Research and Technology Organisations RTOs or small technology firms.

Abgenix has the in-house capabilities of carrying the preclinical testing up to the end of phase II, when the value perceived by the buyer substantially increases. Abgenix has collaborative arrangements with multiple pharmaceutical and biotechnology companies involving its XenoMouse technology.

News August 23,